ASH Annual Meeting and Exposition | Conference

Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo

December 16th 2014

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Duvelisib Produces Responses in Indolent Non-Hodgkin Lymphoma

December 16th 2014

Duvelisib (IPI-145), an inhibitor of PI3K-δ and PI3K-γ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD

Tyrosine Kinase Inhibitor Shows Promise in AML

December 15th 2014

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML

December 9th 2014

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Brentuximab Vedotin Combination Shows Promise in Hodgkin Lymphoma

December 9th 2014

Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.

Ibrutinib Combination Produces High Response Rate in Relapsed/Refractory MCL

December 9th 2014

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

December 9th 2014

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL

December 9th 2014

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

Stem Cell Transplant Feasible, Highly Effective for HIV-Associated Lymphoma

December 8th 2014

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

December 8th 2014

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma

December 8th 2014

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

December 8th 2014

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

IDH2-Targeting Agent Has Positive Early Results in AML

December 8th 2014

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

CAR T-Cell Therapy Elicits High Response Rate in Pediatric ALL

December 7th 2014

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

December 7th 2014

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL

December 7th 2014

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

December 7th 2014

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Brentuximab Vedotin Delivers Unprecedented Post-Transplant PFS Benefit in Relapsed Hodgkin Lymphoma

December 7th 2014

Patients with relapsed and difficult-to-treat Hodgkin lymphoma who received brentuximab vedotin had an unprecedented 50% higher likelihood of continuing to experience PFS at 2 years.

Anti-CD38 Antibodies Highly Effective in Multiple Myeloma

December 7th 2014

Two studies spotlighted at the 2014 ASH Annual Meeting characterized the efficacy of treatment with anti-CD38 monoclonal antibodies in the frontline setting and for patients with refractory disease.

NEXT PAGE
PREVIOUS PAGE